Dexmedetomidine-Propofol and Ketamine-Propofol During Upper Gastrointestinal System Sedation

Brief Summary

Sedation with dexmedetomidine-propofol or ketamine-propofol was planned in patients with upper gastrointestinal endoscopy.

Intervention / Treatment

  • Drug: Dexmedetomidine

Condition or Disease

  • Anesthesia; Reaction

Phase

Study Design

Study type: Observational
Status: Completed
Study results: No Results Available
Age: 18 Years to 60 Years   (Adult)
Enrollment: 60 ()
Funded by: Other

Masking

Clinical Trial Dates

Start date: Oct 18, 2019
Primary Completion: Feb 20, 2020
Completion Date: Mar 13, 2020
Study First Posted: May 22, 2020
Results First Posted: Aug 31, 2020
Last Updated: May 22, 2020

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Patients between 18 and 60 years in American Society of Anesthesiologists (ASA) I and II groups were included. Patients that had severe organ disease, allergies to study drugs, refused to participate in the study were excluded. Cases were randomized into the dexmedetomidine-propofol group (Group D, n=30) and ketamine-propofol group (Group K, n=30). Cardiac monitoring, peripheral oxygen saturation, bispectral index (BIS) monitoring were performed. Group D received 1mg/kg dexmedetomidine+0.5mg/kg propofol intravenous (iv) bolus, 0.5 μg/kg/h dexmedetomidine+ 0.5 mg/kg/h propfol infusion. Group K received 0.125 mL/kg bolus, 0.125 mL/kg/h ketamine+ propofol = ketofol infusion (ketofol was prepared with 4 mg propofol+2 mg ketamine). Patients were followed up with a Ramsay Sedation Scale (RSS) of≥4. Mean, standard deviation, mean, lowest-highest frequency and ratio values were used in descriptive statistics of the data, SPSS 22.0 program was used for the analyses.

Eligibility Criteria

Sex: All
Minimum Age: 18
Maximum Age: 60

More Details

NCT Number: NCT04399226
Other IDs: umutkan
Study URL: https://ClinicalTrials.gov/show/NCT04399226
Last updated: Jun 17, 2022